Is Bajaj Healthcare the Best Stock in Its Sector? A Look at the Numbers

Bajaj Healthcare CMP Rs 328 (15 Sep 2026). Market cap Rs 1,125 Cr. ROE 8.81%. P/E 63.76x versus Industry P/E 51.01x.

Updated: 15 Sept 2026 • 10:42 am

Posted by:

Is Bajaj Healthcare the Best Stock in Its Sector? A Look at the Numbers

Quick Answer

Bajaj Healthcare is one of the names investors compare when screening the Healthcare sector, built on a 8.81% return on equity and a P/E of 63.76x against an Industry P/E of 51.01x. Bajaj Healthcare Ltd manufactures active pharmaceutical ingredients, intermediates and formulations, supplying both domestic and export pharmaceutical markets from its Gujarat-based facilities. Whether Bajaj Healthcare is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.

Is Bajaj Healthcare the best stock in its sector? The stock trades on the NSE at Rs 328 as of 15 September 2026, within its 52-week range of Rs 272.35 to Rs 515.90. Bajaj Healthcare Ltd manufactures active pharmaceutical ingredients, intermediates and formulations, supplying both domestic and export pharmaceutical markets from its Gujarat-based facilities.

Bajaj Healthcare sits in the Healthcare sector, and its 8.81% ROE and 63.76x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.

Click Here – Get Free Investment Predictions

Table of Contents

About Bajaj Healthcare

Bajaj Healthcare Ltd manufactures active pharmaceutical ingredients, intermediates and formulations, supplying both domestic and export pharmaceutical markets from its Gujarat-based facilities. At a market capitalisation of Rs 1,125 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Bajaj Healthcare the Best Stock in Its Sector?

Bajaj Healthcare makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 8.81% ROE with a 63.76x P/E against the sector’s 51.01x Industry P/E. Bajaj Healthcare’s 63.76x P/E is above the 51.01x Industry P/E despite an 8.81% ROE that trails larger API and formulation peers, suggesting the valuation is pricing in future capacity-led growth rather than current returns.

Metric	Bajaj Healthcare
CMP (NSE)	Rs 327.90
52-Week High / Low	Rs 515.90 / Rs 272.35
Market Cap	Rs 1,125 Cr
P/E (TTM) vs Industry P/E	63.76x vs 51.01x
P/B	2.11
ROE	8.81%
EPS (TTM)	Rs 5.24
Dividend Yield	0.45%
Debt to Equity	0.47

Compare Bajaj Healthcare Against Other Healthcare Sector Stocks

How Bajaj Healthcare Compares Against Its Healthcare Sector Peers

The table below sets Bajaj Healthcare against 3 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 3 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Bajaj Healthcare	1,125	63.76	8.81%	0.47
Laurus Labs	1,06,460	97.64	16.77%	0.48
Divis Laboratories	2,47,576	84.64	15.32%	0.00
Neuland Laboratories	30,197	60.66	19.42%	0.16
Peer average (3 companies)	–	80.98	17.17%	0.21

Against this peer set, Bajaj Healthcare’s 8.81% ROE is below the 17.17% peer average, and its P/E of 63.76x runs below the peer average of 80.98x. Bajaj Healthcare’s 63.76x P/E is above the 51.01x Industry P/E despite an 8.81% ROE that trails larger API and formulation peers, suggesting the valuation is pricing in future capacity-led growth rather than current returns.

What Makes Bajaj Healthcare Worth Watching in Healthcare

API manufacturing base: A focus on APIs and intermediates positions Bajaj Healthcare in the upstream, manufacturing-heavy part of the pharma value chain.
Moderate leverage: A debt to equity ratio of 0.47 is manageable for a capital-intensive API manufacturer expanding capacity.
Premium valuation relative to current returns: A 63.76x P/E against an 8.81% ROE is a rich multiple for the current level of capital efficiency, above even the 51.01x Industry P/E.

Bajaj Healthcare Valuation: Is It Justified?

Bajaj Healthcare’s 63.76x P/E is above the 51.01x Industry P/E despite an 8.81% ROE that trails larger API and formulation peers, suggesting the valuation is pricing in future capacity-led growth rather than current returns. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Download the Univest iOS App or Univest Android App to track Bajaj Healthcare and other Healthcare sector stocks.

How to Track Bajaj Healthcare Before You Invest

Before deciding whether Bajaj Healthcare deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

Open the Univest Screener and search for Bajaj Healthcare to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Bajaj Healthcare earns a place in the best stock in its sector conversation on the strength of a 8.81% ROE and a P/E of 63.76x against a 51.01x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Is Bajaj Healthcare the best stock in its sector?

Ans. Bajaj Healthcare has a 8.81% ROE and trades at 63.76x P/E against a 51.01x Industry P/E, and compares below the peer average ROE of 17.17% in this article’s named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Bajaj Healthcare?

Ans. Bajaj Healthcare was trading at Rs 327.90 on the NSE as of 15 September 2026, within its 52-week range of Rs 272.35 to Rs 515.90.

What sector does Bajaj Healthcare belong to?

Ans. Bajaj Healthcare is classified under the Healthcare sector on Univest.

How does Bajaj Healthcare compare to its sector peers on P/E?

Ans. Bajaj Healthcare’s P/E of 63.76x is below the 80.98x average of the 3 named peers compared in this article.

What is Bajaj Healthcare’s return on equity?

Ans. Bajaj Healthcare reported a return on equity of 8.81%, which is below the 17.17% average of its named peers in this comparison.

Should I invest in Bajaj Healthcare based on its sector position?

Ans. Bajaj Healthcare’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.